January 6th, 2015

Biosimilars in 2015: What Can We Expect?

On Friday, March 6th, 2015 the FDA approved Sandoz’s Zarxio, the first official biosimilar that will be made available in the U.S.

Zarxio, a recombinant granulocyte colony-stimulating factor used to boost white blood cells after cancer treatments, is the long-awaited biosimilar for filgrastim (Amgen’s Neupogen).

The FDA noted in their briefs that Zarxio was “highly similar” to the brand biologic and had “no clinically meaningful differences between the proposed product and the reference product in terms of safety, purity, and potency”. The FDA stated that “robust” pharmacokinetic and pharmacodynamic comparative studies supported biosimilarity with the original filgrastim.

I’ll admit it, as a pharmacist the topic of biosimilars peaks my interest. Europe has been marketing biosimilars for years now, and the Food and Drug Administration (FDA) is developing long-awaited standards so that this process can be initiated in the U.S. And it looks like this week, the process is finally starting.

But there are many questions still to be answered:

  • What biologics are in-line to be the first approved biosimilars?
  • Where will health care providers find information about biologic interchange with biosimilars?
  • How much cheaper will a biosimilar be as compared to its brand counterpart?
  • Can pharmacists automatically make a switch between a biologic and a biosimilar without prescriber approval?

The current state of biosimilars, and their FDA standards, is still in process in the U.S. Take a look at our article to review the controversial issues, learn facts about biosimilars, and see upcoming biosimilars in the pipeline for approval down the road.


Updated 3/11/2015

September 23rd, 2014

Drugs.com Adds Mayo Clinic Disease Reference

Drugs.com is pleased to announce it has licensed select content from Mayo Clinic to provide more timely and trustworthy medical condition and disease information.

The articles include detailed information about medical diseases such as allergies, back pain, depression, erectile dysfunction, and type 2 diabetes. Each article includes informative sections which may include an overview, symptoms, when to see a doctor, how to prepare for your appointment, disease causes, tests and diagnosis, disease risk factors and prevention strategies. We know you find this new addition to our website useful and reliable.

Mayo Clinic http://www.mayoclinic.org/ is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. Their mission is to inspire hope and contribute to health and well-being by providing the best care to every patient through integrated clinical practice, education and research.

Visit the new Mayo Clinic disease information here: http://www.drugs.com/mcd/

July 14th, 2014

Fox News Features Drugs.com Medication Guide app

Thanks to Fox News for showcasing the Drugs.com Medication Guide app today. Very much appreciated.

Available in both the Apple App store and the Google Play store, this is a great app for ultra-quick research and/or keeping track of multiple meds.

Check out the video at the link below…


And check out the apps here…


April 3rd, 2014

Consumer Reports Gives the Thumbs Up to the Drugs.com Pill Identifier App

Consumer Reports just put out a review of seven pill identifier apps. Here’s a snippet…

“We reviewed seven apps that can help identify the pills you take, and liked two of them a lot: Drugs.com Pill Identifier and Epocrates Pill ID. The others—CVS/Pharmacy Pill Identifier, iPharmacy Pill Identifier, Pill Finder, Prescription Pill Identifier, and ID My Pill—didn’t fare as well.

The Drugs.com app, the user-friendlier of the two, also provided links to relevant news about each drug. ”

View the full report here…


And you can download the app here…



March 4th, 2014

Introducing the Drugs.com redesign

After a lot of effort from our NY brand agency and in-house designers, we have started to roll out a new look for Drugs.com. First step is a logo and menu change. At the same time we have a team working through updating all the mobile apps, Facebook, Google+, Twitter and Youtube channels. Wow, we’re spread far and wide nowadays.

It’s not just a new brand image. As part of the upgrade process, we will also be pushing out significant usability upgrades over the coming months. We are channeling most of our resources into improving the user experience (UX is the geek term) making everything better, faster, simple and clear. We hope you’ll like it.

February 10th, 2014

Q4 2013 Drug Sales Data Released: Tecfidera Growth On a Rapid Transit

Drugs.com has released the latest U.S. drug sales data. While the ranking of the top three drugs by sales — Abilify, Nexium and Humira — remains the same, Lilly’s Cymbalta drops from fourth to seventh and forfeits close to $319 million in sales due to generic availability. Nexium’s growth tapers too, possibly due to looming patent loss and an up-and-coming Rx-to-OTC switch. Crestor, AstraZeneca’s top cholesterol drug with market exclusivity until 2016, slides up one notch to number four, and GSK’s Advair Diskus returns to round out the top five. Tecfidera, predicted to be a blockbuster in Biogen Idec’s multiple sclerosis portfolio, continues to gain strength with a 20 percent climb in sales.

View the full data here…

February 6th, 2014

Drugs.com and TrialReach to Give Patients Access to Drugs In Development

Drugs.com, the leading online clinical drug resource, and TrialReach are partnering to provide patients with information and access to treatments that are still under development. This partnership will bring TrialReach’s patient-centric content and tools directly to the 25+ million people who visit Drugs.com every month.

From a patient’s perspective, clinical trials offer more treatment options when the standard ones fail. They also give patients the opportunity to participate in medical research that may also help other patients in the future.

We hope to have integration complete during the current quarter.

More information here:


December 30th, 2013

Looking Back at 2013

The end of the year is always a good time to reflect back on healthcare innovations, major drug approvals, and frankly, things that could have possibly gone a tad bit better. From advances in hepatitis C virus treatments, to over-the-counter availability of emergency contraception, the year had lots of positive healthcare hits.

But a few misses were thrown in too – let’s not forget about the doping scandal with Lance Armstrong on Oprah Winfrey’s network, and the government’s faulty Healthcare.gov website that left millions without a way to join Obamacare.

Most important, and most gratifying for many patients, are the new drug approvals made by the FDA in 2013. These new medications open healthcare options for patients that range from increased adherence due to easier dosing regimens, to extending survival time for patients with metastatic cancer, to a viral cure of a liver-robbing disease.

It’s easy for some people to argue that the U.S. healthcare system is flawed. It’s the negative stories that stand out — those are the ones that everyone remembers. But it’s important at the end of the year to remember the successes, too, and be hopeful for more healthcare advances, and fewer healthcare misses, in 2014.

For more details, watch the End of Year Round-Up Slideshow

November 7th, 2013

Q3 2013 Drug Sales Data Released: Top Five Drugs Each Post Over $1 Billion in Sales

The latest U.S. drug sales data has been released by Drugs.com. Rankings for the top five drugs by sales remain unchanged in the third quarter. Otsuka’s antipsychotic Abilify and AstraZeneca’s Nexium retain their number one and two spots, respectively. Nexium, the top proton pump inhibitor faces sizable over-the-counter competition, a looming Rx-to-OTC switch, and patent loss in 2014. AbbVie’s Humira, Eli Lilly’s Cymbalta, and AstraZeneca’s Crestor round out the remaining top five.

View the full data here…

September 26th, 2013

Drugs.com Recognizes American Pharmacists Month

Pharmacists Recognized for Their Valuable Role in Healthcare

American pharmacist with senior man in pharmacyOctober is a special month here at Drugs.com – it’s American Pharmacists Month, spearheaded by the American Pharmacists Association (APhA). We are pharmacists ourselves, so naturally we like to take time this month to recognize the many pharmacists in the U.S. that work to improve patient care, expand healthcare access, and foster medication knowledge. From the bottom of our hearts, we say “Thank you!”

Pharmacists, numbering over 300,000 strong in the U.S., are one of the most accessible health care professionals in the nation. Pharmacists work at local community and retail pharmacies, in major hospitals, outpatient clinics, managed health care organizations, pharmaceutical industry, and academia around the country. Pharmacists are an integral member of the health care team in today’s society and work to promote the safe and effective use of increasingly complex treatment regimens.

You, or someone you know, has probably had that experience of caring for a sick child at night and seeking some advice at the pharmacy. Pharmacists remain available after normal business hours to counsel concerned parents about prescription medication use, and clear up confusing questions about the myriad of over-the-counter (OTC) remedies. Pharmacists immunize patients against the flu and other infections, review a patient’s array of medications to screen for possible drug interactions, and offer help in seeking out a lower-cost medication alternative. It’s no wonder that pharmacists consistently rank near the top of the list of the most trusted professionals in the U.S.

Today, a U.S. pharmacist must undergo extensive education and on-site training, culminating in the Doctor of Pharmacy professional degree. Registered pharmacists are licensed in the respectives states in which they work, and must complete required yearly professional continuing education. Many pharmacists go on to complete specialized residency or fellowship training, certifications in diabetes care and training, and board certification in many diverse areas including ambulatory care, oncology, and nutrition support.

This month, take the time to speak to your pharmacist, and have them review your entire medication profile, including OTC medicines, vitamins and herbal supplements. Inform them of your health conditions, be sure they know your medication and food allergies, and let them know if you prefer to utilizing cost-saving generic medications. By maintaining an ongoing relationship with your pharmacist, you can help to protect yourself and your family. Pharmacists truly are the last line of defense against medication dosing errors, drug interactions, and allergy screening. Get to know your pharmacist – always your partner in good health.